Press "Enter" to skip to content

Merck to buy cancer drug developer Peloton for $1.05 billion in cash

The company had been looking to go public and gave a pricing range of $15 to $17 per share for its initial public offering last week.

Original source:

Also Read:   Doctors, cops to get vaccine on priority: Maharashtra minister